Supply / Manufacturing · Southeast Asia · Announced 2 Jul 2026
Biocon → Duopharma Biotech
Duopharma Biotech won Malaysian Health Ministry insulin contracts worth over MYR 225 million, supplied by Biocon from its Johor plant, covering human insulin, glargine and aspart for public facilities.
Parties: Biocon (India) → Duopharma Biotech (Malaysia)
- Deal type
- Supply / Manufacturing
- Value
- See terms
- Territory
- Malaysia – public healthcare facilities nationwide
- Therapeutic area
- Metabolic / Diabetes
- Assets
- recombinant human insulin; insulin glargine; insulin aspart
- Announced
- 2 Jul 2026
Our analysis
Why this matters
Duopharma Biotech, through its subsidiary Duopharma (M) Sdn Bhd, has been awarded Malaysian Ministry of Health contracts worth more than MYR 225 million to supply insulin to public healthcare facilities nationwide. Biocon, through Biocon Sdn Bhd, will supply the products from its integrated manufacturing facility in Johor. The awards cover recombinant human insulin (a three-year agreement of about MYR 155.27 million), insulin glargine (two years, about MYR 18 million) and insulin aspart (two years, about MYR 52.5 million). They were reported on 2 July 2026 and mark a decade of collaboration between the two companies.
For CEOs, this is the localization model at work: a foreign originator manufactures in-country and a local partner holds the government tender relationship.
The full analysis is free to read with a work email on this page.
Source: The Star (Malaysia)